Vendor Intelligence Report: Crush Research

Published 3 Jul 2026. 27-page investigative report on who is behind Crush Research: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Crush Research is a narrow-strength vendor, not a vendor-wide green light. Across 4 Finnrick lab tests, Crush Research has 4 pass / 0 fail, for an overall pass rate of 100%. The record covers one Finnrick-tested product: Retatrutide, now sold by Crush as Triple Agonist. That makes Crush a reasonable shortlist option for this molecule relative to untested sellers, but the evidence should not be carried over to the rest of its expanded catalog.

The lab story is clean on identity/pass-fail but less simple on fill reliability. The report ties Triple Agonist back to Retatrutide by CAS number, then separates that positive identity signal from a material underfill outlier in the Finnrick field notes. Under stricter Finnrick methodologies, fill precision weighs harder, so the public pass record is best read as favorable but batch-sensitive.

Beyond the vial, Crush is more accountable than many peptide storefronts because Rory Hester is a visible founder/operator with media and social traces. The legal counterparty is less settled: a preserved Wyoming filing lead resolves to a different LLC, no matching Crush Research filing was located in the searched registries, and Hester’s own co-owner language leaves one control person unnamed. The report also tracks the .com-to-.shop channel path, current credit-card and international-shipping posture, and a coupon-driven promotion network where disclosure quality is uneven.

Inside the full report:

  • Appendix A Finnrick Laboratory Data for the Retatrutide/Triple Agonist record, with methodology-divergence and fill-sensitivity exhibits
  • Product-identity analysis tying Triple Agonist to Retatrutide by CAS number and current product-page evidence
  • Wyoming Secretary of State eFNum mismatch review and corporate-filing search limits
  • Founder, co-owner, address, domain, and shared-suite control trail
  • Janoshik COA posture, sourcing-opacity assessment, and buyer batch-matching guidance
  • X/web affiliate-code scan with disclosure classifications and promotion examples

Risk assessment

  • Triple Agonist (Retatrutide) fill-quantity inconsistency risk — high: March 4, 2026 Retatrutide sample measured 11.9 mg vs 15.3 mg labeled, a 22.1% underfill, despite 4/4 Finnrick passes for the product.
  • Independent-testing coverage gap outside Triple Agonist risk — medium: Finnrick covers only Retatrutide/Triple Agonist in the supplied data; other peptides and lab supplies are not independently covered.
  • Supply-chain opacity risk — medium: No manufacturers, origin countries, supplier audits, or chain-of-custody records are disclosed; COAs verify submitted samples, not source control.
  • Corporate-governance transparency risk — medium: No confirmed Crush Research corporate filing was located; the preserved Wyoming eFNum matched KS Marketing Research Group, LLC, and the co-owner remains unidentified.
  • Affiliate-promotion disclosure risk — medium: The X/web scan found 10 code/link promoters or owner-linked channels, with 7 lacking clear disclosure in the scan classification.
  • Early-stage operating and fulfillment stability risk — medium: Founded in October 2025 with rapid catalog expansion, site/payment transitions, stock volatility, and presale terms including pending testing and no credit cards.